JPRN-jRCT2071220001已完成1 期
A phase I study of SK-0348 in healthy adult subjects (Single dose)
Kenji Asano0 个研究点目标入组 46 人开始时间: 2022年3月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
研究概览
简要总结
SK-0348 had no safety concerns, while dose-response relationship could not be determined in pharmacokinetic and pharmacodynamic evaluations since the low plasma concentrations of SK-0348 were observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 40age old（—）
- 性别
- Male
入选标准
- •1. Subjects aged 20 years or older but less than 40 years (at the time of informed consent)
- •2. Subjects with BMI (weight (kg)/[height (m)]2) of 18.5 to less than 25.0 (at the time of screening)
- •3. Subjects considered eligible for this study based on the results of screening examination by the investigator or sub-investigator.
- •4. Subjects who have the capacity to consent and have obtained written consent from the subject.
排除标准
- •1. Subjects with current medical history.
- •2. Subject with a history of eye, hepatic, renal, cardiovascular, hematologic, endocrine, gastrointestinal, respiratory, urologic, psychiatric, or neurological disease, xerostomia, or infectious disease that the investigator or sub-investigator judges to affect the safety of the subject or the evaluation of the investigational drug.
- •3. Subjects with skin conditions as follows.
- •1) Skin diseases such as eczema, dermatitis, pigmentary abnormalities, etc.
- •2) With a history of atopic dermatitis.
- •3) Have skin hypersensitivity.
- •4) With abnormality at the site of administration of the investigational drug.
- •4. Subjects with clinically abnormalities in the screening test or 12-lead electrocardiogram at rest on the day of admission.
- •5. Subjects who have body hair that prevents administration of the investigational drug, have tattoos or birthmarks on the site of administration of the investigational drug, or have frequent sunburns on the skin.
- •6. Subjects with a complication or a history of drug dependence or alcohol dependence.
- •7. Subjects with a complication or a history of drug hypersensitivity.
- •8. Subjects with a complication or a history of food allergy.
- •9. Subjects who had an average of 20 grams or more of alcohol per day.
- •10. Subjects who used any drug or supplement within 2 weeks prior to hospitalization for this study.
- •11. Subjects who smoked within 4 weeks prior to the screening test.
- •12. Subjects who had food or beverages containing grapefruit (juice or pulp) within 3 days prior to hospitalization for this study.
- •13. Subjects who had ingested food or beverages containing St. John's wort (St. John's wort) within 1 week prior to hospitalization to the study.
- •14. Subjects who have donated 400 mL whole blood within 12 weeks prior to hospitalization in this study, 200 mL whole blood within 4 weeks, or blood component(plasma component, platelet component) within 2 weeks.
- •15. Subjects who had a positive result for HIV antigen/antibody, HBs antigen, or HCV antibody, or a positive reaction to syphilis serology or urine drug test at screening.
- •16. Subjects with a positive for SARS-CoV-2 nucleic acid detection test on the day of hospitalization.
- •17. Subject who is in the opinion of the investigator or sub-investigator, unsuitable in any other way to participate in this study.
研究者
相似试验
已完成
1 期
SK-5307 P I single-dose study.JPRN-jRCT2071220045Kenji Asano38
已完成
3 期
Phase III Study of S-877503 in Adult Patients with ADHD -long term extension studyAttention-deficit/hyperactivity disorderJPRN-jRCT2080223177Shionogi & Co., Ltd.191
未知
3 期
A clinical pharmacological study of SK-0403Type 2 diabetes mellitusJPRN-jRCT2080221260SANWA KAGAKU KENKYUSHO CO.,LTD.20
招募中
3 期
Efficacy and safety clinical trial in SKD-001Pts with abnormal chest shadows that are difficult to biopsy using nomal bronchoscopic procedureJPRN-jRCT2052220174Miyake Kotaro22
已完成
不适用
Phase 1 study to evaluate safety and pharmacokinetic property of DNP001 in patients with JL1 postive acute leukemia or myelodysplastic syndromeKCT0002421Asan Medical Center18